What is Insulin Glargine?

A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.

Insulin Glargine in the library · · Human Trials · What are peptides?

613 registered trials · 996 indexed papers · 1086 human / 2 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.

Type: Long-acting insulin analog.

Definition (National Library of Medicine)

“A recombinant long acting insulin and hypoglycemic agent that is used to manage blood glucose in patients with diabetes mellitus.”

  • MeSH: Insulin Glargine

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Insulin Glargine is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (613)

TrialPhaseStatusYearEnrolled
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsPhase 3recruiting20261778
CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trialnot yet recruiting202650
Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes ManagementPhase 4recruiting2026200
Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletesenrolling by invitation202660
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 DiabetesPhase 4not yet recruiting2026324
Randomized Transition to Gla-300 in Pediatric Type 1 Diabetes: CGM-Derived OutcomesPhase 4completed202571
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesPhase 3active not recruiting2025877
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusPhase 4completed2025105
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsPhase 4recruiting20251316
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes SubjectsPhase 2completed2025275
Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)recruiting2025176
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)Phase 3active not recruiting2025580
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial InsulinPhase 3active not recruiting2025580
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesPhase 4enrolling by invitation2025100
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in IndiaPhase 4completed2024153
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 DiabetesPhase 3completed2024412
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)Phase 3completed2024485
To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy SubjectsPhase 1completed202424
iGlarLixi CGM Study in Chinese T2D Individuals After OADsPhase 4recruiting2024678
Effect of Topical Insulin on Healing Rate of Pemphigus LesionsPhase 2completed202420
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 DiabetesPhase 3completed2024401
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 DiabetesPhase 3completed2024393
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®Phase 1completed2024114
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)recruiting2024430
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetesrecruiting2024430
RCT Glargine vs NPH for Treatment of DM in PregnancyPhase 3recruiting2024160
Comparing the Safety and Efficacy of Insulin GLARGINE and DEGLUDEC in Glucocorticoid Induced HYPERGLYCEMIA in Hospitalized Patients".Phase 4completed202379
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskPhase 3completed20232749
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource SettingsPhase 4completed2023400
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)Phase 3completed2023795
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus PatientsPhase 3completed2023224
Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)Phase 4completed2023107
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic ControlPhase 3completed2023243
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.Phase 3completed2023423
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic DrugsPhase 3completed2023513
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemiacompleted202390
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 DiabetesPhase 4unknown2023210
Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational DiabetesPhase 2active not recruiting2022120
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)Phase 3completed2022573
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 DiabetesPhase 3completed2022550

Peer-reviewed studies (996)

PaperAuthorsJournalYearType
Bedtime Snack Composition and Overnight Glycemic Profiles in Children and Adolescents with Type 1 Diabetes Using Multiple Daily Injections: A Randomized Crossover StudyGüneş Kaya D et al.Nutrients2026Randomized Controlled Trial
Glucose-lowering in type 2 diabetes may be mediated by improved proinsulin processing without better β-cell compensationRetnakaran R et al.American journal of physiology. Endocrinology and metabolism2026Randomized Controlled Trial
iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic controlTaybani ZJ et al.Frontiers in endocrinology2026Observational Study
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trialJi L et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Efficacy and Safety of Once-Weekly Semaglutide [amount hidden] as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)Rodbard HW et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D StudyZhang S et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitusSun Y et al.Endocrine2026Randomized Controlled Trial
Pharmacokinetics, Pharmacodynamics, and Safety of Once-Weekly Insulin Efsitora Alfa in Chinese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled TrialLiu H et al.Advances in therapy2026Randomized Controlled Trial
Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trialLuo J et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CNNi J et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical TrialsWharton S et al.Diabetes, obesity & metabolism2026Clinical Trial, Phase III
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical TrialGiorgino F et al.JAMA2026Randomized Controlled Trial
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D StudyLi X et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled TrialRosenstock J et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 DiabetesConnery L et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Real-world experience with insulin glargine U300 in pediatric type 1 diabetes: glycemic control, insulin requirements, and patient-reported outcomesAltun I et al.BMC endocrine disorders2026Observational Study
Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized TrialBergenstal RM et al.Diabetes care2026Randomized Controlled Trial
Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulinParikh M et al.The Journal of clinical endocrinology and metabolism2026Randomized Controlled Trial
Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)Gonzalez JS et al.Diabetes care2026Randomized Controlled Trial
Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)Kahn SE et al.Diabetes care2026Randomized Controlled Trial
Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trialNovodvorský P et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Efficacy and hypoglycaemia outcomes of once-weekly insulin icodec versus once-daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1-5Cheng AYY et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetesLandgraf W et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D studyGu W et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover TrialJang HN et al.Diabetes & metabolism journal2026Randomized Controlled Trial
Comparative Effectiveness of Switching From First-Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical RegistryRabbone I et al.Pediatric diabetes2025Observational Study
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trialGuo L et al.The lancet. Diabetes & endocrinology2025Randomized Controlled Trial
Efficiency of Gla-300 versus Gla-100 Across Age Groups in People Living with Type 2 Diabetes in France: A Post Hoc Analysis of an Observational Longitudinal StudyDarmon P et al.Advances in therapy2025Observational Study
Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) CohortPop-Busui R et al.Diabetes care2025Randomized Controlled Trial
Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4Guan H et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Insulin Glargine?

A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.

How many registered human trials study Insulin Glargine?

The PeptideWhiz trial index lists 613 registered trials for Insulin Glargine, the most recent from 2026.

How much published research exists on Insulin Glargine?

The PeptideWhiz paper index links 996 PubMed papers to Insulin Glargine; by study type, 1086 human and 2 animal studies.

Which conditions is Insulin Glargine researched for?

Anti-aging & longevity, Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Concussion, traumatic brain injury & stroke recovery, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Diabetic retinopathy and glaucoma, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Heart repair: after heart attack, heart failure & enlarged heart, High cholesterol and statins, High-demand jobs: military, fire, police, EMT (and combat-sport athletes), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low blood pressure and orthostatic hypotension, Lung health, asthma & COPD, Neuropathy and CRPS, Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Skin, hair loss, wounds & mast-cell/histamine reactivity.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research